BICO Group AB (publ) has repurchased convertible bonds to a total nominal amount of SEK 118m
November 22, 2024 6:00 pmOn March 19, 2021, BICO Group AB (publ) (“BICO” or the “Company”) issued senior unsecured convertible bonds with a total nominal amount of SEK 1,500,000,000 (the “Convertible Bonds”).
On November 22, 2024, the Company repurchased Convertible Bonds with a total nominal amount of SEK 118,000,000 at a purchase price of 83.63 percent (excluding accrued but unpaid interest) of the Convertible Bond’s nominal amount. The total purchase consideration for the bought-back Convertible Bonds thereby amounted to SEK 98,682,500 (the “Buyback”). Following the Buyback, BICO’s holdings of the Convertible Bonds totals a nominal amount of SEK 118,000,000.
The rationale behind the Buyback was to optimize BICO’s capital structure and made possible by the Company’s strong liquidity position. BICO will continue to evaluate the bond market and may from time to time repurchase further Convertible Bonds in the market, subject to the liquidity needs of the Company.
Carnegie Investment Bank AB (publ) acted as Dealer Manager in the Buyback.
For further information, please contact:
Jacob Thordenberg, CFO, BICO Group AB
Phone: +46 735 34 88 84
E-mail: jt@bico.com
The information was submitted for publication, through the agency of the contact person set out above, on November 22, 2024 at 6pm CET.
BICO is a lab automation partner and provider of selected workflows to pharma and biotech. With 46,000+ instruments installed in over 65 countries, BICO products, software, and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 12,000 publications. Operating through three business areas – Lab Automation, Life Science Solutions, and Bioprinting – BICO strives towards the vision to enable and automate the life science lab of the future. BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com